Barrett Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Barrett Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.71M	Buy	14,222 +39	+0.3%	+$9.26K	0.16%	71
2021 Q4	$3.12M	Sell	14,183 -14,427	-50%	-$2.81M	0.12%	76
2021 Q3	$5.19M	Sell	28,610 -872	-3%	-$170K	0.24%	64
2021 Q2	$5.94M	Sell	29,482 -10,199	-26%	-$2.13M	0.27%	59
2021 Q1	$8.53M	Buy	39,681 +5,420	+16%	+$1.19M	0.42%	51
2020 Q4	$8.1M	Sell	34,261 -8,384	-20%	-$1.92M	0.42%	49
2020 Q3	$11.6M	Buy	42,645 +16,863	+65%	+$4.65M	0.68%	43
2020 Q2	$7.49M	Buy	25,782 +14,467	+128%	+$3.92M	0.48%	47
2020 Q1	$2.69M	Buy	+11,315	New	+$2.6M	0.21%	65
2019 Q4	–	Sell	-145	Closed	-$25K	–	383
2019 Q3	$25K	Sell	145 -45	-24%	-$7.96K	﹤0.01%	274
2019 Q2	$35K	Hold	190	–	–	﹤0.01%	256
2019 Q1	$35K	Hold	190	–	–	﹤0.01%	260
2018 Q4	$31K	Buy	+190	New	+$32.9K	﹤0.01%	263
2016 Q2	–	Sell	-165	Closed	-$13K	–	394
2016 Q1	$13K	Buy	+165	New	+$14.9K	﹤0.01%	304

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Barrett Asset Management's VRTX Position: Q1 2022 in Review

Barrett Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.27% in Q1 2022, buying an estimated $9.26K and bringing the position to 14,222 shares worth $3.71M. The position accounts for 0.16% of the portfolio, ranked #71.

Barrett Asset Management first reported a position in VRTX in Q1 2016 and has held it in 14 quarters since. The position peaked at $11.6M in Q3 2020. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Barrett Asset Management held 14,222 shares of Vertex Pharmaceuticals worth $3.71M as of Q1 2022.
Barrett Asset Management bought 39 Vertex Pharmaceuticals shares in Q1 2022, an estimated $9.26K.
Vertex Pharmaceuticals made up 0.16% of Barrett Asset Management's portfolio in Q1 2022, its #71 holding.
Barrett Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 14 quarters since.
Barrett Asset Management's Vertex Pharmaceuticals position peaked at $11.6M in Q3 2020.
1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Barrett Asset Management's 13F filing for Q1 2022, filed 16 May 2022.